Plain-English translation of NCT05165745 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is about PrEP, a medication that helps prevent HIV infection. Researchers want to understand why some women and transgender individuals choose to take this medication, why others decide not to, and what kinds of support and monitoring options work best for people using it.
Many women and transgender individuals face barriers to accessing and staying on HIV prevention medication. This study aims to understand their preferences and experiences so researchers can design better support systems that help people continue with the medication if they choose to take it.
You likely qualify if…
You likely don't qualify if…
You will complete online surveys about your background, health, and preferences regarding HIV prevention medicine. If you're taking the medication, you'll share information about how often you take it and can receive personalized text or email reminders. You may also be asked to provide a small blood sample to check medication levels and share your thoughts on self-testing options. Some participants will be invited for in-depth interviews to discuss their decisions about the medication.
AI-generated summary from trial data · Jul 20, 2026 · Not medical advice
United States
Columbia University
Collaborators
Merck Sharp & Dohme LLC
Enrollment target
~175 participants
Started
October 2021
Primary completion
October 2026
Age range
18 Years and older
Last updated on clinicaltrials.gov in September 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Deborah Theodore, MD
Columbia University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.